Navigation Links
Abbott and Oasmia Pharmaceutical Announce Exclusive Distribution Agreement for Paccal(R) Vet, a New Chemotherapeutic Agent for Dogs
Date:7/10/2009

ind, and if approved, has the potential to become an important tool for treating Grade II and Grade III mast cell tumors - both of which can be life-threatening in dogs."

"Oasmia is pleased to announce this agreement with Abbott for the largest market within veterinary medicine," said Julian Aleksov, chief executive officer, Oasmia. "Abbott brings a well established veterinary sales organization and a long tradition in North America, and this agreement is an acknowledgement of the significant commercial potential of Paccal Vet."

In the United States alone an estimated one million dogs are diagnosed with cancer annually. One out of every four dogs will die of cancer and it is the number one cause of death in dogs over two years of age. Mast cell tumors are among the most common skin tumors in dogs, and are often difficult to manage. Most of these dogs will be treated with surgery, but many patients may require additional or alternative treatment with radiotherapy and chemotherapy. Radiotherapy is not widely available, and where it is an option it remains complicated, expensive, and requires the patient to undergo several procedures where anesthesia is necessary.

About Paccal(R) Vet

With the retinoid based unique platform XR-17, Oasmia developed a water soluble formulation of paclitaxel (Paccal(R) Vet), that does not require premedication and abolishes Cremophor(R) EL related side effects. Two clinical trials have been performed in client owned dogs with tumors refractory to standard treatment. The results are very promising, both regarding tolerability and tumor response. In one clinical study of dogs with Grade II/III mast cell tumors, the overall response rate (either complete disappearance of all signs of cancer or the tumor shrinks or stops growing completely) was 69.5 percent.(1) The studies also show that the pharmacokinetic and side-effect profiles in dogs are supported by parallel trials i
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Abbott Hosts Conference Call for Second-Quarter Earnings
2. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
3. Schmidt & Clark, LLP: FDA Reports Show Abbott Labs Subsidiary Failed to Disclose Parasite Eye Infections Tied to Contact Lens Solution
4. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
5. Abbott Declares 342nd Consecutive Quarterly Dividend
6. Abbott Announces Launch of Next-Generation Embolic Protection System
7. Abbott Announces New EAS(R) Myoplex(R) Strength Formula Nutrition Shake and Debuts Bottle Packaging
8. Abbotts TRILIPIX(R) (Fenofibric Acid) in Combination With Rosuvastatin Calcium Helps Patients With Mixed Dyslipidemia and Type 2 Diabetes Meet American Diabetes Association Lipid Targets
9. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
10. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
11. Abbott to Present at Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 03, 2015 , ... Each year, the ... policymakers, public servants, activists, corporate executives, entrepreneurs, health care professionals, and others have ... process led the magazine to tap the National League for Nursing’s outspoken CEO, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healthegy, a leading producer of ... who will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( ... Boston. , Larry Renfro, CEO of Optum, will deliver the morning address. In ...
(Date:9/2/2015)... ... 2015 , ... The Western Connecticut Health Network (WCHN) has ... to establish the Abraham and Mildred Goldstein Endowment Fund for Ovarian Cancer Research. ... known gynecologic oncologist Thomas J. Rutherford, MD, PhD as its network physician director ...
(Date:9/2/2015)... (PRWEB) , ... September 02, ... ... provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics ... to Insights Educational Series. The series enables pharmaceutical researchers to participate in ...
(Date:9/2/2015)... ... September 02, 2015 , ... Care Providers and their medical ... that include EOBs, payments, and payment related documents. AD-EOB A/R helps them sort, ... their billing, with one efficient process and interface,“ stated Rich Caproni, AliusDoc’s Director ...
Breaking Medicine News(10 mins):Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:AliusDoc Launches Enhanced AD-EOB A/R Data Capture Solution to Streamline Processing of Payment-Related Documents Together with EOBs 2
... say, , THURSDAY, Aug. 20 (HealthDay News) -- A ... can impair fertility, requires no surgery and is extremely ... the accuracy of the new approach, which spots the ... which the researchers also acknowledged. , Until now, a ...
... New ... , ... 20, 2009 -- ConnextionsHealth today introduced the Rapid Ramp Call Verification Solution to ... and Medicaid Services (CMS). The guideline , issued August 7, 2009, and effective for ...
... , List of cities and times below. Team will ... other advocates will be filming comedy commercials against "Obama,s Death Care," including ... , WASHINGTON, Aug. 20 The following was released today by ... "It is refreshing to see the rage expressed at ,town hall meetings., ...
... , WAYNE, Pa., Aug. 20 Forty-nine companies ... 2009 Spine Technology Award. The entry deadline was August 15. Any ... to enter. , , The Spine Technology Awards ... increased recognition to exemplary and innovative spine surgery products and the ...
... women, can be relieved by the use of acupuncture and ... the Sahlgrenska Academy, University of Gothenburg, Sweden. Nearly 10% ... The syndrome expresses itself as a large number of small ... the production of hormones and an increase in the secretion ...
... first time, it has been shown that patients who ... those who receive kidney transplants from deceased donors. ... hemodialysis patients compared to kidney transplant recipients," published in ... , a total of 1,239 patients were followed for ...
Cached Medicine News:Health News:New Way Found to Diagnose Endometriosis 2Health News:New Way Found to Diagnose Endometriosis 3Health News:ConnextionsHealth Introduces Turnkey, Rapid Ramp Call Verification Solution 2Health News:ConnextionsHealth Introduces Turnkey, Rapid Ramp Call Verification Solution 3Health News:Healthcare and Abortion: Randall Terry Leads Protests and Press Conferences in 10 Cities in Five States 2Health News:49 Companies Submit Products for First Spine Technology Awards; Entries Now Closed 2Health News:Acupuncture may bring relief for a common condition in women 2Health News:Night home hemodialysis shown to be as good as transplant in treating kidney failure 2
(Date:9/2/2015)... Physicians Rx Pharmacy ("PRxP") today announced that ... President and Chief Executive Officer.  Mr. Bernstein, ... Officer for Soleo Health Specialty Infusion Services, will, as ... be responsible for leading the rapidly-growing 340B pharmacy services ... Gaston on as the President and CEO of PRxP," ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) has ... (London, UK - November 19-20, 2015)" conference to ... will cover industry case studies, regulatory updates, latest therapies ... Dr Steven Nichols , OINP Specialist Consultant and ... Companies participating include: - Aptar ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced the addition of ... 16-18, 2015)" conference to their offering. Regulatory requirements for ... Peru , Brazil , ... , Paraguay , Venezuela , ... Chile This seminar can be viewed both as ...
Breaking Medicine Technology:Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2
... , , , ... to get all their flu shots as soon as the vaccines ... flu and the H1N1 (swine) flu, according to eight leading national ... eight organizations - the March of Dimes, the American College of ...
... , , , ... FRANCISCO, Sept. 23 Late-breaking data from the SPIRIT IV trial ... achieved superiority in the key safety and efficacy measures of target ... TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS) at one year. With ...
Cached Medicine Technology:Pregnant Women Need Flu Shots 2Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial 2Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial 3Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial 4Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial 5Abbott's XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial 6
Manual Lensmeter....
The Marco Lensmeter 201 features internal readings for the presbyopic practitioner or those who prefer to work in subdued lighting where external readings are difficult....
... million pixel image provides excellent ... for all types of diagnostic ... glaucoma to diabetic retinopathy evaluation. ... filmless, instant review, digital filing ...
Manual lensmeter with AO target, high and wide field eyepiece and better marking dots....
Medicine Products: